Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in advanced cancer with FGF/FGFR aberrations
NCT02846766Phase 2Withdrawn
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in cancer. Planned start Jul 2018; status: withdrawn.
02
Drugs
lenvatinib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02846766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846766.